Best of ASCO 2025, Seattle

Seattle, WA US
June 13, 2025 to June 14, 2025

This CME-accredited oncology conference, Best of ASCO 2025, Seattle, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2025 ASCO® Annual Meeting (ASCO2025) in June 2025. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2025 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

  • Binay Shah, MD, MHA - Binaytara

Conference Chair:

  • Petros Grivas, MD, PhD - Fred Hutchinson Cancer Center, University Of Washington
  • David Zhen , MD - Fred Hutchinson Cancer Center , University Of Washington

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  • Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  • Explain how to effectively manage side-effects associated with cancer treatment
  • Review abstracts presented at ASCO® 2025 and discuss their application in clinical settings

You may also be interested in

Best of ASCO 2025, Shreveport

This CME-accredited oncology conference, Best of ASCO 2025, Shreveport, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.
Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-017-H01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
01/22/2025
Course expires: 
09/22/2025
Event starts: 
06/13/2025 - 8:00am PDT
Event ends: 
06/14/2025 - 12:15pm PDT
Cost:
$350.00
Add to calendar: 

Day 1 - June 13, 2025

All times are listed in Pacific Daylight Time (PDT)

12:00 PM – 01:00 PM  Registration, Lunch, and Exhibits

01:00 PM – 01:05 PM  Welcome 

01:05 PM – 02:35 PM  Session 1 - Hematologic Malignancies

Session Chair: Livia Hegerova, MD

01:05 PM – 01:35 PM  MDS/Leukemias - Roland Walter, MD, PhD, MS

01:35 PM – 02:05 PM  Multiple Myeloma - Danai Dima, MD

02:05 PM – 02:35 PM  Lymphoma & CLL - David Aboulafia, MD

02:35 PM – 02:45 PM  Break and Exhibits

02:45 PM – 04:25 PM  Session 2 - General Oncology

Session Chair: Nellowe Candelario, MD

02:45 PM – 03:15 PM  Sarcoma - Min S. Park, MD

03:15 PM – 03:45 PM  Cutaneous Malignancies - Shailender Bhatia, MD

03:45 PM – 04:05 PM  Advances in CNS Tumor - Vyshak Venur, MD

04:05 PM – 04:25 PM  Management of Cervical and Endometrial Cancers - Recent Updates - Elise J. Simons, MD, FACOG

04:25 PM – 05:10 PM  Session 3 - Tumor-Board Style Discussion: Challenging Cases

Session Chair: Elise J. Simons, MD, FACOG

Case-Based Discussion: Chirag A. Shah, MD MPH

Panel Discussion

05:10 PM – 06:15 PM  Reception, Networking, and Exhibits 

 

Day 2 - June 14, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, and Exhibits

08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Justin Marquart

08:30 AM – 10:00 AM  Session 4 - Genitourinary Cancer

Session Chair: Petros Grivas, MD, PhD

08:30 AM – 09:00 AM  Prostate Cancer - Hiba Khan, MD, MPH

09:00 AM – 09:30 AM  Bladder Cancer - Rosa Nadal Rios, MD, PhD

09:30 AM – 10:00 AM  Kidney Cancer - Lisa Tachiki, MD

10:00 AM – 10:30 AM  Break and Exhibits

10:30 AM – 12:00 PM  Session 5 - Gastrointestinal Cancer

Session Chair: David B. Zhen, MD

10:30 AM – 11:00 AM  Upper GI Cancer - David B. Zhen, MD

11:00 AM – 11:30 AM  Hepatobiliary and Pancreatic Malignancies - Gentry King, MD

11:30 AM – 12:00 PM  Colorectal Cancer - Stacey Cohen, MD

12:00 PM – 01:00 PM  Lunch and Exhibits

Product Theater Sponsored by Astellas in Discovery Breakout Room

Topic: BIOCHEMICAL RECURRENCE (BCR) IN PROSTATE CANCER: Definitions, Risk Factors, and Guideline-Directed Management

Speaker: Evan Y. Yu, MD

*This is a non-CME accredited activity*

01:00 PM – 02:30 PM  Session 6 - Breast Cancer

Session Chair: Xiaowen Wang, MD, PhD

01:00 PM – 01:30 PM  Early-Stage Breast Cancer - William Rayford Gwin III, MD

01:30 PM – 02:00 PM  Metastatic Breast Cancer 1: Metastatic Hormone Receptor-Positive HER2 Negative - Christos Vaklavas, MD

02:00 PM – 02:30 PM  Metastatic Breast Cancer 2: HER2-Positive and Triple-Negative Breast Cancer - Vidhya Nair, DO

02:30 PM – 03:00 PM  Break and Exhibits

03:00 PM – 03:45 PM  Session 7 - Tumor-Board Style Discussion: Challenging Cases

Session Chair: Tanya A. Wahl, MD

Case-Based Discussion: Sid Devarakonda, MD; Ronan Hsieh, MD

Panel Discussion: Joseph Rosales, MD; Lei Deng, MD; Shih-Li (Bruce) Lin, MD

03:45 PM – 05:15 PM  Session 8 - Thoracic Oncology

Session Chair: Keith D. Eaton, MD, PhD

03:45 PM – 04:15 PM  Early-Stage Non-Small Cell Lung Cancer - Nicholas P. Giustini, MD

04:15 PM – 04:45 PM  Metastatic Non-Small Cell Lung Cancer - Lei Deng, MD

04:45 PM – 05:15 PM  Small Cell Lung Cancer - Diane Tseng, MD, PhD

05:15 PM  Adjourn

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Petros Grivas, MD, PhD

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Astellas Pharma;.
has a financial relationship (Professional Services) with Gilead Sciences;.
has a financial relationship (Professional Services) with BostonGene;.
has a financial relationship (Professional Services) with Fresenius Kabi;.
has a financial relationship (Professional Services) with Lucence Health;.
has a financial relationship (Professional Services) with PureTech;.
has a financial relationship (Professional Services) with G1 Therapeutics;.
has a financial relationship (Professional Services) with Aadi Biosciences;.
has a financial relationship (Professional Services) with CG Oncology;.
has a financial relationship (Professional Services) with Strata Oncology;.
has a financial relationship (Professional Services) with Immunity Bio;.
has a financial relationship (Professional Services) with Asieris Pharmaceuticals;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with QED Therapeutics;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Grant Or Contract) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with EMD Serano;.
has a financial relationship (Grant Or Contract) with G1 Therapeutics;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Acrivon Therapeutics;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.
has a financial relationship (Grant Or Contract) with Genentech;.

David Zhen, MD

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Bristol Meyers Squibb;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals/Zymeworks, Inc;.
has a financial relationship (Professional Services) with A2 Biotherapies;.
has a financial relationship (Professional Services) with Excelixis;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Medigene;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Cornerstone Pharmaceuticals;.
has a financial relationship (Professional Services) with Daiichi Sankyo, Inc;.
has a financial relationship (Professional Services) with Eli Lilly;.
has a financial relationship (Professional Services) with Legend Biotech;.
has a financial relationship (Professional Services) with Roche/Genentech;.
has a financial relationship (Professional Services) with Pfizer/Seagen;.
Session Chair(s)

Nellowe Candelario

has no relevant financial relationships to disclose at this time.

Keith Eaton, MD, PhD

has no relevant financial relationships to disclose at this time.

Livia Hegerova

has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Grant Or Contract) with Agios;.
has a financial relationship (Grant Or Contract) with Rigel;.

Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah

has no relevant financial relationships to disclose at this time.

Xiaowen Wang

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Replimune;.
has a financial relationship (Professional Services) with Regeneron;.

Stacey Cohen

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Agenus;.
has a financial relationship (Independent contractor) with Delcath;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Taiho;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Exact Sciences;.
has a financial relationship (Independent contractor) with Incyte;.

Lei Deng, MD

has a financial relationship (Travel) with MJH Life Sciences;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Travel) with Merck;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Grant Or Contract) with BridgeBio Oncology Therapeutics;.

Danai Dima, MD

has no relevant financial relationships to disclose at this time.

Nicholas Giustini, MD

has a financial relationship (Other) with Curio Science;.

William Gwin

has a financial relationship (Other) with Astra Zeneca;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Grant Or Contract) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Veanna Therapeutic;.
has a financial relationship (Grant Or Contract) with Amazon;.

Hiba Khan, MD, MPH

has no relevant financial relationships to disclose at this time.

Gentry George King, MD

has no relevant financial relationships to disclose at this time.

Rosa Nadal Rios, Associate Professor.  Division of Hematology and Oncology. University of Washington School of Medicine

has no relevant financial relationships to disclose at this time.

Vidhya Nair, DO

has no relevant financial relationships to disclose at this time.

Min Park, MD, MS

has a financial relationship (Stock) with Eli Lilly;.
has a financial relationship (Stock) with Johnson & Johnson;.
has a financial relationship (Stock) with Thermo Fisher Scientific;.

Elise Simons, Clinical Assistant Professor, Division of Gynecologic Oncology, University of Washington

has no relevant financial relationships to disclose at this time.

Lisa Tachiki, MD

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with SeaGen;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Financial Support) with CytomX;.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with Celgene/Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with ImmunoGen/AbbVie;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Jazz;.
has a financial relationship (Grant Or Contract) with Kura;.

David Zhen, MD

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Bristol Meyers Squibb;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals/Zymeworks, Inc;.
has a financial relationship (Professional Services) with A2 Biotherapies;.
has a financial relationship (Professional Services) with Excelixis;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Medigene;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Cornerstone Pharmaceuticals;.
has a financial relationship (Professional Services) with Daiichi Sankyo, Inc;.
has a financial relationship (Professional Services) with Eli Lilly;.
has a financial relationship (Professional Services) with Legend Biotech;.
has a financial relationship (Professional Services) with Roche/Genentech;.
has a financial relationship (Professional Services) with Pfizer/Seagen;.
Case Presenter(s)

Sid D

has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Johnson and Johnson;.
has a financial relationship (Grant Or Contract) with AZ;.
has a financial relationship (Professional Services) with Nuvation;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Oncohost;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with Caris;.
has a financial relationship (Professional Services) with BI;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Catalyst;.

Ronan Hsieh, MD, MS

has a financial relationship (Financial Support) with Curio Science;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Travel) with Medscape;.
has a financial relationship (Travel) with Merck;.

Bruce Lin, Medical Oncologist

has a financial relationship (Grant Or Contract) with Exelixis;.
has a financial relationship (Grant Or Contract) with Jazz Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Relay Therapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Tvardi Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Cardiff Oncology;.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Chirag Shah, MD MPH

has a financial relationship (Professional Services) with Glaxo Smith Kline;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Natera;.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • AstraZeneca
  • Exact Sciences
  • Novartis

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-017-H01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binaytara.org/ASCOSeattle

 

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.